Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK -positive NSCLC: Implications for disease assessment and management-Reference-Cited by-同舟云学术

Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK -positive NSCLC: Implications for disease assessment and management

Published:2015-06 Issue:3 Volume:88 Page:355-359
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ou Sai-Hong Ignatius,Klempner Samuel J.,Azada Michele C.,Rausei-Mills Veronica,Duma Christopher

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference18 articles.

1. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas;Brandsma;Lancet Oncol,2008

2. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients;Brandes;J Clin Oncol,2008

3. MGMT gene silencing and benefit from temozolomide in glioblastoma;Hegi;N Engl J Med,2005

4. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study;Gadgeel;Lancet Oncol,2014

5. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases;Kodama;Cancer Chemother Pharmacol,2014

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant combination treatment with checkpoint inhibitors, chemotherapy, and BRAF/MEK inhibitors for BRAFV600E glioblastoma results in sustained response: A case report;Neuro-Oncology Advances;2024-01-01

2. Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review;Cancer/Radiothérapie;2023-12

3. Management strategies for intracranial progression in ALK-positive non-small cell lung cancer: a real-world cohort study;Journal of Neuro-Oncology;2023-12

4. Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy;Frontiers in Pharmacology;2023-08-17

5. Symptomatic Brain Radiation Necrosis in an Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Patient After Fractionated Stereotactic Radiotherapy While on Alectinib;Cureus;2023-03-09